VisEn will use the additional financing to further advance its proprietary fluorescence in vivo imaging product pipelines, and to expand its commercial applications and customer support of its marketed products worldwide.
Kirtland Poss, president and CEO of VisEn Medical, said: “Based on our progress since the first Series B closing, the results that customers are achieving with our systems and agents, some key new product launches, and the strong commercial traction we are already seeing in 2008, our board and our investors have decided to increase their support to accelerate our growth.”